VEDOLIZUMAB FOR INFLAMMATORY BOWEL DISEASE IN CLINICAL PRACTICE – EXPERIENCE FROM A PROSPECTIVE GERMAN REGISTRY

(1) Charité,Berlin,Germany

(2) Gastroenterology Practice,Altenholz,Germany

(3) Gastroenterology Practice,Münster,Germany

(4) Asklepios,Hamburg,Germany

(5) Gastroenterology Practice,Berlin,Germany

(6) University of Kiel,Kiel,Germany

(7) Braunschweig Hospital,Braunschweig,Germany

(8) University of Dresden,Dresden,Germany

(9) University of Jena,Jena,Germany

(10) Gastroenterology Practice,Herne,Germany

(11) Gastroenterology Practice,Frankfurt,Germany

(12) Gastroenterology Practice,Heidelberg,Germany

(13) University of Erlangen,Erlangen,Germany

(14) Hannover Medical School,Hannover,Germany

(15) Gastroenterology Practice,Hamburg,Germany

(16) Gastroenterology Practice,Minden,Germany

(17) Gastroenterology Practice,Mainz,Germany

(18) University of Lübeck,Lübeck,Germany

(19) Agaplesion,Frankfurt,Germany

(20) University of Münster,Münster,Germany

(21) Gastroenterology Practice,Leipzig,Germany



This item was part of UEG Week 2015

This item can be cited as: United European Gastroenterology Journal; 2015: 2 (Supplement 1)